ImmuPharma plc (LON:IMM – Get Free Report) traded down 18% during mid-day trading on Wednesday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.84 ($0.06). 61,560,121 shares were traded during trading, an increase of 142% from the average session volume of 25,488,205 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Price Performance
The company’s 50 day simple moving average is GBX 1.92 and its 200 day simple moving average is GBX 1.78. The stock has a market cap of £20.74 million, a P/E ratio of -498.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Steel Stocks Soaring After Tariff Announcements
- How to Invest in Small Cap Stocks
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- CD Calculator: Certificate of Deposit Calculator
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
